NEULANDLAB — Neuland Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Annual income statement for Neuland Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,668	7,627	9,369	9,511	11,912
Cost of Revenue
Gross Profit	2,397	3,102	4,049	4,238	5,856
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	6,290	6,904	8,273	8,556	9,609
Operating Profit	378	723	1,096	955	2,303
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	203	529	1,053	822	2,157
Provision for Income Taxes
Net Income After Taxes	164	395	806	638	1,635
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	164	162	806	638	1,635
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	164	162	806	638	1,635
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	13.1	30.5	63	50.8	128
Dividends per Share